Norges Bank’s Vertex Pharmaceuticals VRTX Stock Holding History

Norges Bank’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,176,613	Closed	-$1.44B	–	1371
2025 Q4	$1.44B	Buy	+3,176,613	New	+$1.37B	0.15%	113
2025 Q3	–	Sell	-3,580,356	Closed	-$1.59B	–	1533
2025 Q2	$1.59B	Buy	3,580,356 +216,206	+6%	+$99.6M	0.2%	94
2025 Q1	$1.63B	Sell	3,364,150 -50,174	-1%	-$23.4M	0.23%	82
2024 Q4	$1.37B	Buy	3,414,324 +4,542	+0.1%	+$2.11M	0.18%	98
2024 Q3	$1.59B	Sell	3,409,782 -19,304	-0.6%	-$9.27M	0.22%	82
2024 Q2	$1.61B	Sell	3,429,086 -28,864	-0.8%	-$12.5M	0.24%	72
2024 Q1	$1.45B	Buy	3,457,950 +415,662	+14%	+$176M	0.23%	78
2023 Q4	$1.24B	Buy	3,042,288 +368,382	+14%	+$136M	0.22%	86
2023 Q3	$930M	Buy	2,673,906 +64,995	+2%	+$22.7M	0.19%	106
2023 Q2	$918M	Buy	2,608,911 +79,972	+3%	+$26.9M	0.18%	106
2023 Q1	$797M	Buy	2,528,939 +77,418	+3%	+$23.2M	0.17%	114
2022 Q4	$708M	Buy	2,451,521 +163,049	+7%	+$49.7M	0.17%	121
2022 Q3	$663M	Buy	2,288,472 +61,874	+3%	+$17.8M	0.18%	105
2022 Q2	$627M	Sell	2,226,598 -398,150	-15%	-$107M	0.16%	121
2022 Q1	$685M	Sell	2,624,748 -55,151	-2%	-$13.1M	0.15%	134
2021 Q4	$589M	Buy	2,679,899 +153,719	+6%	+$29.9M	0.12%	159
2021 Q3	$458M	Sell	2,526,180 -21,250	-0.8%	-$4.15M	0.1%	193
2021 Q2	$514M	Sell	2,547,430 -90,096	-3%	-$18.8M	0.11%	176
2021 Q1	$567M	Sell	2,637,526 -133,800	-5%	-$29.4M	0.13%	158
2020 Q4	$655M	Sell	2,771,326 -90,928	-3%	-$20.9M	0.15%	126
2020 Q3	$779M	Buy	2,862,254 +175,851	+7%	+$48.5M	0.21%	85
2020 Q2	$780M	Buy	2,686,403 +148,490	+6%	+$40.3M	0.22%	76
2020 Q1	$604M	Buy	2,537,913 +20,310	+0.8%	+$4.66M	0.22%	86
2019 Q4	$551M	Buy	2,517,603 +135,224	+6%	+$27.4M	0.15%	128
2019 Q3	$404M	Hold	2,382,379	–	–	0.12%	165
2019 Q2	$437M	Hold	2,382,379	–	–	0.14%	149
2019 Q1	$438M	Buy	2,382,379 +85,698	+4%	+$15.8M	0.14%	138
2018 Q4	$381M	Sell	2,296,681 -27,323	-1%	-$4.73M	0.14%	137
2018 Q3	$448M	Sell	2,324,004 -41,203	-2%	-$7.34M	0.15%	138
2018 Q2	$402M	Sell	2,365,207 -69,449	-3%	-$10.8M	0.14%	148
2018 Q1	$397M	Buy	2,434,656 +94,152	+4%	+$15.4M	0.14%	142
2017 Q4	$351M	Buy	2,340,504 +191,180	+9%	+$28.3M	0.13%	166
2017 Q3	$327M	Buy	2,149,324 +125,272	+6%	+$18.9M	0.12%	169
2017 Q2	$261M	Sell	2,024,052 -127,869	-6%	-$15.4M	0.1%	211
2017 Q1	$235M	Buy	2,151,921 +420,366	+24%	+$37M	0.1%	215
2016 Q4	$128M	Buy	1,731,555 +56,502	+3%	+$4.6M	0.06%	333
2016 Q3	$140M	Hold	1,675,053	–	–	0.07%	284
2016 Q2	$144M	Sell	1,675,053 -45,441	-3%	-$3.93M	0.07%	282
2016 Q1	$137M	Sell	1,720,494 -53,627	-3%	-$4.85M	0.07%	276
2015 Q4	$223M	Buy	1,774,121 +4,715	+0.3%	+$569K	0.11%	168
2015 Q3	$184M	Buy	1,769,406 +124,052	+8%	+$15.9M	0.1%	201
2015 Q2	$203M	Buy	1,645,354 +49,305	+3%	+$6.21M	0.1%	195
2015 Q1	$188M	Sell	1,596,049 -15,131	-0.9%	-$1.81M	0.09%	219
2014 Q4	$191M	Buy	1,611,180 +70,910	+5%	+$7.99M	0.1%	200
2014 Q3	$173M	Sell	1,540,270 -1,540,270	-50%	-$147M	0.09%	211
2014 Q2	$292M	Buy	3,080,540 +1,547,708	+101%	+$109M	0.08%	238
2014 Q1	$108M	Hold	1,532,832	–	–	0.06%	301
2013 Q4	$114M	Sell	1,532,832 -371,911	-20%	-$25.9M	0.07%	287
2013 Q3	$144M	Buy	1,904,743 +1,037,398	+120%	+$82.6M	0.08%	232
2013 Q2	$69.3M	Buy	+867,345	New	+$63.9M	0.04%	406

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Norges Bank's VRTX Position: Q1 2026 in Review

Norges Bank sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 3,176,613 shares — an estimated $1.44B sold.

Norges Bank first reported a position in VRTX in Q2 2013 and held it in 50 quarters. The position peaked at $1.63B in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Norges Bank reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Norges Bank sold 3,176,613 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.44B.
Norges Bank first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 50 quarters.
Norges Bank's Vertex Pharmaceuticals position peaked at $1.63B in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Norges Bank's 13F filing for Q1 2026.